摘要
目的探究倍他司汀治疗急性后循环缺血眩晕老年患者的效果。方法本研究为回顾性研究,选取2018年2月至2021年2月郑州大学附属郑州中心医院神经内科收治的160例急性后循环缺血眩晕老年患者,男100例,女60例,年龄(72.05±4.58)岁,年龄范围为66~80岁。采用抽签法分为单药治疗组与联合治疗组,每组80例。单药治疗组给予口服盐酸氟桂利嗪治疗,联合治疗组在此基础上联用倍他司汀治疗,比较治疗后两组患者椎基底动脉血流动力学、生化指标、血液流变学指标及不良反应发生情况。结果治疗后,联合治疗组左侧[(48.64±9.30)cm/s]、右侧[(48.92±8.11)cm/s]及基底动脉血流速度[(47.38±8.14)cm/s]高于单药治疗组[(43.26±7.69)cm/s、(42.58±7.29)cm/s、(42.17±7.26)cm/s];联合治疗组内皮素-1水平[(120.29±19.34)ng/L]低于单药治疗组[(154.16±25.03)ng/L]、降钙素基因相关肽(CGRP)水平[(39.07±6.13)ng/L]高于单药治疗组[(30.64±4.28)ng/L];联合治疗组血浆黏度[(1.30±0.29)mPa/s]、全血黏度[(3.45±0.62)mPa/s]、纤维蛋白原水平[(2.14±0.52)g/L]低于单药治疗组[(2.14±0.23)mPa/s、(4.03±0.28)mPa/s、(3.48±0.27)g/L],差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论盐酸氟桂利嗪联合倍他司汀应用于急性后循环缺血眩晕患者中可有效提高脑血流动力和抑制血管收缩能力,降低血液黏度,且不增加额外不良反应。
Objective To explore the value of betahistine in elderly patients with acute posterior circulation ischemia vertigo.Methods This study was a retrospective study,from February 2018 to February 2021,160 elderly patients with acute posterior circulation ischemia vertigo admitted to the department of Neurology,Zhengzhou Central Hospital Affiliated to Zhengzhou University were selected,including 100 males and 60 females,aged(72.05±4.58)years old,and the age ranging from 66 to 80 years old.Divided into single-agent treatment group and combined treatment group by lottery,80 cases in each group.The single-agent treatment group was given oral flunarizine hydrochloride treatment,and the combined treatment group was treated with betahistine on this basis.After treatment,the two groups of patients were compared with vertebrobasilar artery hemodynamics,biochemical indexes,and hemorheological indexes And the occurrence of adverse reactions.Results After treatment,the left side[(48.64±9.30)cm/s],right side[(48.92±8.11)cm/s]and basilar artery blood flow velocity[(47.38±8.14)cm/s]of the combined treatment group were higher than single-agent treatment group[(43.26±7.69)cm/s,(42.58±7.29)cm/s,(42.17±7.26)cm/s];combined treatment group endothelin-1 level[(120.29±19.34)ng/L]was lower than the single-agent treatment group[(154.16±25.03)ng/L],calcitonin gene-related peptide(CGRP)level[(39.07±6.13)ng/L]was higher than the single-agent treatment group[(30.64±4.28)ng/L];combined treatment group plasma viscosity[(1.30±0.29)mPa/s],whole blood viscosity[(3.45±0.62)mPa/s],fibrinogen level[(2.14±0.52)g/L]were lower than the single-agent treatment group[(2.14±0.23)mPa/s,(4.03±0.28)mPa/s,(3.48±0.27)g/L],the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusions Flunarizine hydrochloride combined with betahistine in patients with posterior circulation ischemic vertigo can effectively improve cerebral blood flow and inhibit vasoconstriction,reduce blood viscosity without adding additional adverse reactions.
作者
陈洁
窦海玲
李世泽
赵松耀
王一凡
Chen Jie;Dou Hailing;Li Shize;Zhao Songyao;Wang Yifan(Department of Neurology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,China)
出处
《中国临床实用医学》
2022年第1期36-39,共4页
China Clinical Practical Medicine
关键词
倍他司汀
盐酸氟桂利嗪
急性后循环缺血眩晕
椎基底动脉血流动力学
Betahistine
Flunarizine hydrochloride
Acute posterior circulation ischemia vertigo
Vertebrobasilar artery hemodynamics
